Navigation Links
BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
Date:7/17/2009

tient's temperature and clinical condition. In this study, the median time to alleviation of symptoms in all 37 evaluable patients treated with either 300 mg or 600 mg peramivir daily was 68.6 hours.

i.v. peramivir 300 mg and 600 mg in both single and multiple doses were generally safe and well-tolerated in these trials. Further analyses of the study data, including secondary efficacy endpoints and detailed safety is underway. Additional data will be submitted for presentation at an upcoming medical meeting.

"The clinical outcomes of these Phase 3 studies are important, especially during the declared influenza pandemic, as they indicate the promise of peramivir as a treatment for influenza," commented Dr. William P. Sheridan, Chief Medical Officer of BioCryst. "The need for additional anti-viral treatment options for influenza remains high. BioCryst is currently finalizing its plans for peramivir Phase 3 studies intended to support U.S. regulatory approval, while continuing to support the pre-emergency use authorization review of peramivir by the U.S. Food & Drug Administration."

"This data represents a significant milestone for BioCryst -- the first Phase 3 studies successfully conducted with a drug candidate discovered by BioCryst," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst. "We congratulate Shionogi on the success of these rapidly completed studies, which have the potential to lead to the first regulatory approval for peramivir."

Shionogi has stated that the Company is making its best effort to file its New Drug Application and to receive a manufacturing approval as soon as possible in Japan.

About Peramivir

Peramivir is an anti-viral agent that inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. Peramivir has demons
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
2. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
3. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
4. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
5. BioCryst Updates Peramivir Clinical Development Plan
6. BioCryst Provides Forodesine HCl Update
7. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
8. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
9. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
10. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
11. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... TAIPEI , Sept. 1, 2015 ... 2,500 employees, SHL Group has rapidly reached 3,000 ... yet rapid growth in the injectable drug delivery ... A global leader in the design ... SHL offers innovative designs, robust manufacturing capabilities, a ...
(Date:9/1/2015)... Sept. 1, 2015 Pressure BioSciences, Inc. ... in the development and sale of broadly enabling, ... the worldwide life sciences industry, today announced the ... the Company,s PCT Platform could play a significant ... This role is based on PCT,s unique ability ...
(Date:9/1/2015)...  Abbott (NYSE: ABT ) announced today positive one-year ... comparing the safety and effectiveness of Abbott,s fully dissolving ... market-leading, permanent drug eluting stent. The trial was conducted ... and enrolled 400 people with coronary artery disease, the ... be featured at a late-breaking session today at ESC ...
Breaking Medicine Technology:SHL Group Reaches Major Milestone of 3000 Employees 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4
... , NEW YORK, November 17 ... biomarkers will help identify and monitor patients at risk,of developing ... are,cared for in prenatal clinics around the world. , ... highly-respected National,Institute of Child and Human Development of the National ...
... , NEW YORK, Nov. 17 ... Street is the first laser hair removal center in New ... system by Cynosure, Inc., a leading developer and manufacturer of ... Elite MPX, which incorporates Cynosure,s patented MultiPlex sequencing technology, is ...
Cached Medicine Technology:New Study Heralds Use of Blood Biomarkers to Predict Preeclampsia 2New Study Heralds Use of Blood Biomarkers to Predict Preeclampsia 3Romeo and Juliette Laser Hair Removal Is First Center in New York City to Own Cynosure's New Elite MPX(TM) Laser System 2
(Date:9/1/2015)... ... September 01, 2015 , ... ... Nelson, D.O., has joined its medical management team as an Associate Medical Director. ... all sizes and types in the U.S. and abroad. , Dr. Nelson ...
(Date:9/1/2015)... ... ... Two of Washington D.C.’s most respected chefs are using their global expertise and ... “the next big thing” in the culinary world by Elle Spain, award-winning culinary duo ... and reclaiming culinary traditions on the brink of extinction. According to Amy and Luigi, ...
(Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading audit, ... being named a “Best of the Best” firm in the U.S., as well as ... “Best of the Best” in the U.S., selected exclusively on performance in specific areas ...
(Date:9/1/2015)... ... September 01, 2015 , ... METTLER ... now available. With the Connectivity Kit, EasySampler data is automatically transferred to, ... control experiment, on a touchscreen platform. , EasySampler fully automates the sampling ...
(Date:9/1/2015)... OH (PRWEB) , ... September 01, 2015 , ... Mercy ... – has devoted the 10th of its monthly Mercy Health: Helping You Be Well ... affecting one in seven men. , In a concise video on Mercy Health’s ...
Breaking Medicine News(10 mins):Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2
... FL, June 30, 2010 The Florida Biomedical Research ... to three scientists from the Florida campus of The ... to Glenn Micalizio, an associate professor in the Scripps ... five years; Thomas Bannister, assistant professor of medicinal chemistry ...
... Scientists at the Stanford University School of Medicine ... finding is significant because the existence of such a ... source of debate. It may also explain why current ... human patients. "These cells lack the traditional ...
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, June ... daughter avoid dementia much later on in life, a new study ... to play. Canadian researchers believe they,ve found a link between ... senior years. The study doesn,t definitively prove that exercise lowers ...
... People who care about improving the environment in life may ... Europe have developed two new and unusual methods of body ... compost method that turns bodies into soil that could ... the topic of an article in the current issue of ...
... Glinert and Jon Schommer, the associate head of the ... University of Minnesota, have examined the corporate websites dedicated ... startling lack of consistency in an industry where advertising ... (FDA). "Communicating via a website is common ...
... ... ... -- Practical solutions and protocols will once again be exchanged at Cambridge Healthtech ... Boston. The four meetings comprising the event (Optimizing Cell Culture Technology, Affinity ...
Cached Medicine News:Health News:Scripps Research scientists share $2 million in Florida state research grants 2Health News:Melanoma-initiating cell identified by Stanford scientists 2Health News:Melanoma-initiating cell identified by Stanford scientists 3Health News:Melanoma-initiating cell identified by Stanford scientists 4Health News:Exercise May Guard Girls Against Dementia in Senior Years 2Health News:Linguistics professor examines manufacturers' prescription drug websites 2Health News:Cambridge Healthtech Institute Announces its Second Annual "The Bioprocessing Summit" 2Health News:Cambridge Healthtech Institute Announces its Second Annual "The Bioprocessing Summit" 3
Insert only, Pilling-Weck medium clip size...
Pilling-Weck, small clip size, 10mm, rotatable take apart...
Ethicon, small clip size, 10mm, rotatable take apart...
Solid phase capture sandwich ELISA assay using a microwell format....
Medicine Products: